LockeJohnsonBryanMD

Hematology • Augusta, GA

Hematologic Oncology

Associate Professor of Medicine

Join to view full profile

Dr. Bryan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bryan's full profile

Already have an account?

Office
1411 Laney Walker Blvd
Augusta, GA 30912
Phone+1 706-721-6744

Fax+1 706-721-5566

Summary

Dr. Locke Bryan is a hematologist in Augusta, GA and is affiliated with Augusta University Medical Center. He received his medical degree from University of Mississippi School of Medicine and has been in practice 9 years. He specializes in hematologic oncology and is experienced in hematology / oncology and stem cell transplant.

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Vermont Medical CenterResidency, Internal Medicine, 2008 - 2011
University of Mississippi School of MedicineClass of 2008

Certifications & Licensure

GA State Medical License 2015 - 2025
IL State Medical License 2012 - 2017
VT State Medical License 2008 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission Start of enrollment: 2015 Sep 01
Terminated
Phase 2
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2017 Apr 21
Active, not recruiting
Phase 2
Study of IMPT-314 in R/R Aggressive B-cell NHL Start of enrollment: 2023 May 09
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

23 citations
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investiga...
Locke J Bryan, Carla Casulo, Pamela B Allen, Scott E Smith, Hatice Savas
JAMA Oncology. 2023-05-01
145 citations
Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.
V.G. Chinchar, Locke Bryan, U Silphadaung, Edward J. Noga, D Wade
Virology. 2004-06-01
41 citations
The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.
Michal Kuczma, Zhi-Chun Ding, Tao Li, Tsadik Habtetsion, Tingting Chen
Oncotarget. 2017-12-05

Abstracts/Posters

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
Locke J. Bryan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Antibiotic Use May Affect Efficacy of Cancer ImmunotherapiesMarch 3rd, 2018
Antibiotics Influence Cancer Treatment EfficacyMarch 3rd, 2018
Scientists Work to Strengthen the Synergy of Chemotherapy and Immunotherapy Against CancerApril 17th, 2017